NEUROCRINE BIOSCIENCES INC Business Operations Contracts & Agreements
10 Contracts & Agreements
- Collaboration Agreements (9 contracts)
- Development Agreements (1)
- Collaboration and License Agreement dated November 22, 2021 between Heptares Therapeutics Limited and the Company (Filed With SEC on February 11, 2022)
- Collaboration and License Agreement dated March 31, 2015 between Mitsubishi Tanabe Pharma Corporation and the Company (Filed With SEC on May 5, 2021)
- First Amendment to Collaboration and License Agreement Dated August 31, 2011 between the Company and Abbott International Luxembourg S.a.r.l (Filed With SEC on May 5, 2021)
- Collaboration Agreement dated June 15, 2010, by and between Abbott International Luxembourg S.a.r.l. and the Company as amended on August 31, 2011 (Filed With SEC on May 5, 2021)
- Amendment No. 1 to Collaboration and License Agreement dated June 14, 2019 between Voyager Therapeutics, Inc. and the Company (Filed With SEC on July 29, 2019)
- COLLABORATION AGREEMENT dated June 15, 2010 by and between AbbottInternational Luxembourg S.à r.l. and Neurocrine Biosciences, Inc. EXHIBIT INDEX (Filed With SEC on February 11, 2016)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on April 30, 2015)
- COLLABORATION AGREEMENT dated June 15, 2010 by and between Abbott International Luxembourg S.à r.l. and Neurocrine Biosciences, Inc. (Filed With SEC on July 29, 2010)
- Contract Number: 43031148 COLLABORATION AND LICENSE AGREEMENT Dated June 16, 2010 BY AND BETWEEN BOEHRINGER INGELHEIM INTERNATIONAL GmbH AND NEUROCRINE BIOSCIENCES, INC. TABLE OF... (Filed With SEC on July 29, 2010)
- On December 21, 2006, the Company announced that Wendell Wierenga, Ph.D, Executive Vice President of Research and Development has resigned from the Company. Dr. Wierenga will... (Filed With SEC on December 22, 2006)
